Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.78 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339732 | 0.92 | KCNH2 (0.80) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5943324 | 0.90 | KCNH2 (0.72) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5340351 | 0.90 | KCNH2 (0.79) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL8253791 | 0.88 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| Mk-0873 SCHEMBL4950462 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| Mk-0873 SCHEMBL29372259 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| Mk-0873 SCHEMBL29496418 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5336548 | 0.87 | KCNH2 (1.00) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5340138 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5943413 | 0.86 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | MERCK FROSST CANADA LTD. (CA) | 2006-02-23 | — | — | US | claimed |
| EP-1592419-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | Merck Frosst Canada & Co. (CA) | 2005-11-09 | — | — | EP | claimed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | claimed |
| WO-2009052624-A9 | INHALATION COMPOSITIONS COMPRISING MONTELUKAST ACID AND A PDE-4 INHIBITOR OR AN INHALED CORTICOSTEROID | MERCK FROSST CANADA LTD. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009052624-A1 | COMBINATION THERAPY | MERCK FROSST CANADA LTD. (CA) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009052625-A1 | NOVEL CRYSTALLINE SALTS OF MONTELUKAST | MERCK FROSST CANADA LTD. (CA) | 2009-04-30 | — | — | WO | disclosed |
| US-7312334-B2 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO. INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312334-B2 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO. INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007036029-A1 | AEROSOL POWDER FORMULATION COMPRISING SIEVED LACTOSE | MERCK FROSST CANADA LTD. (CA) | 2007-04-05 | — | — | WO | disclosed |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | MERCK FROSST CANADA LTD. (CA) | 2006-02-23 | — | — | US | disclosed |
| US-20060019981-A1 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO., INC. | 2006-01-26 | — | — | US | disclosed |
| US-6909002-B2 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| WO-2004048377-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1397359-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-6677351-B2 | USEFUL IN TREATMENT OF ASTHMA AND INFLAMMATION | MERCK FROSST CANADA & CO. (CA) | 2004-01-13 | — | — | US | disclosed |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-05-22 | — | — | US | disclosed |
| WO-2002094823-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | PDE4A 2/4885PDE4B 1/4885PDE4C 8/4885 |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE7A | PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885 |
| US-20060019981-A1 | Method of preparing inhibitors phosphodiesterase-4 | PDE4A, PDE5A, PDE3A | PDE4A 1/4885PDE4B 4/4885PDE4C 9/4885 |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.